Evidence map›Paper›PMID 32632897›Full record

ArticlePathology oncology research : POR2020

Concordance Between Biopsy and Radical Prostatectomy Gleason Scores: Evaluation of Determinants in a Large-Scale Study of Patients Undergoing RARP in Belgium.

C Soenens, P Dekuyper, G De Coster, N Van Damme, E Van Eycken, T Quackels, T Roumeguère, B Van Cleynenbreugel, S Joniau, F Ameye and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. The prognostic value ofFrontiers in oncology · 2023
    Article
  6. Prostate Cancer Biomarker Development: National Cancer Institute's Early Detection Research Network Prostate Cancer Collaborative Group Review.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

C SoenensDepartment of Urology, AZ Maria Middelares, Ghent, Belgium. charlotte.soenens@azmmsj.be.ORCID http://orcid.org/0000-0002-1000-0990
P DekuyperDepartment of Urology, AZ Maria Middelares, Ghent, Belgium.
G De CosterBelgian Cancer Registry, Brussels, Belgium.
N Van DammeBelgian Cancer Registry, Brussels, Belgium.
E Van EyckenBelgian Cancer Registry, Brussels, Belgium.
T QuackelsDepartment of Urology, Erasmus Hospital, Brussels, Belgium.
T RoumeguèreDepartment of Urology, Erasmus Hospital, Brussels, Belgium.
B Van CleynenbreugelDepartment of Urology, University Hospital of Leuven, Leuven, Belgium.
S JoniauDepartment of Urology, University Hospital of Leuven, Leuven, Belgium.
F AmeyeDepartment of Urology, AZ Maria Middelares, Ghent, Belgium.
Be-RALP registry
AZ Maria Middelares · BEErasmus Hospital · BEKU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To determine whether Gleason scores were concordant between prostate biopsies (bGS) and the definitive resection specimen (pGS) excised with robot-assisted radical prostatectomy (RARP); to identify clinical and pathological factors that might predict upgrading; and to evaluate how upgrading affected outcome. Between 2009 and 2016, 25 Belgian centers participated in collecting prospective data for patients that underwent RARP. We analyzed the concordance rate between the bGS and the pGS in 8021 patients with kappa statistics, and we compared concordance rates from different centers. We assessed the effect of several clinical and pathological factors on the concordance rate with logistic regression analysis. The concordance rate for the entire population was 62.9%. Upgrading from bGS to pGS occurred in 27.3% of patients. The number of biopsies was significantly associated with concordance. Older age (>60 y), a higher clinical T stage (≥cT2), a higher PSA value at the time of biopsy (>10 ng/ml), and more time between the biopsy and the radical prostatectomy were significantly associated with a higher risk of upgrading. Positive margins and PSA relapse occurred more frequently in upgraded patients. Center size did not significantly affect the concordance rate (p = 0.40).This prospective, nationwide analysis demonstrated a Gleason score concordance rate of 62.9%. Upgrading was most frequently observed in the non-concordant group. We identified clinical and pathological factors associated with (non)-concordance. Upgrading was associated with a worse oncological outcome. Center volume was not associated with pathological accuracy.

Indexed as

BelgiumBiopsy, NeedleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm GradingProspective StudiesProstatectomyProstatic NeoplasmsRobotic Surgical ProceduresCenter sizeConcordanceGleason scoreProstate cancerUpgrading

Identifiers

PMID32632897
OpenAlexW3038856960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.